Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

Inclusion Criteria: * Having participated in Novartis study CAMN107A2109, and * Written signed and dated informed consent prior to any study procedures being performed. Exclusion Criteria: * Impaired cardiac function, * Use of therapeutic coumarin derivatives (i.e., warfarin, acenocoumarol, phenprocoumon) up to the day before study drug administration; Other concurrent severe and/or uncontrolled medical conditions, * Patients who are currently receiving treatment with any of the medications that have the potential to prolong the QT interval, * patients who have undergone a major surgery and have not recovered from side effects of such therapy within 15 days, * Patients who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control, OR * Patients unwilling or unable to comply with the protocol. Other protocol -defined inclusion/exclusion criteria may apply